EINSMED

Insmed is a commercial-stage biopharmaceutical company focused on serious and rare diseases, with a core strength in respiratory and inflammatory disorders and an expanding early-stage genetic medicine platform. The company markets ARIKAYCE for refractory MAC lung disease and BRINSUPRI for non-cystic fibrosis bronchiectasis, giving it two commercial products. Its late-stage pipeline includes treprostinil palmitil inhalation powder (TPIP) for pulmonary vascular and fibrotic lung diseases, while earlier programs include INS1201, an intrathecal AAV9 micro-dystrophin gene therapy for Duchenne muscular dystrophy. Beyond its marketed products, Insmed highlights internal innovation platforms spanning protein deimmunization, RNA end-joining, synthetic rescue, and AI-enabled protein engineering. Overall, Insmed is a rare-disease-focused biotech that has transitioned from a single-product company into a broader commercial and pipeline-driven organization.